AR103653A1 - Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen - Google Patents

Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen

Info

Publication number
AR103653A1
AR103653A1 ARP160100363A ARP160100363A AR103653A1 AR 103653 A1 AR103653 A1 AR 103653A1 AR P160100363 A ARP160100363 A AR P160100363A AR P160100363 A ARP160100363 A AR P160100363A AR 103653 A1 AR103653 A1 AR 103653A1
Authority
AR
Argentina
Prior art keywords
polyethylene glycol
copolymers based
abiraterone acetate
complex
pharmaceutically acceptable
Prior art date
Application number
ARP160100363A
Other languages
English (en)
Inventor
Filipcsei Genovva
Glavinas Hristos
Tvs Zsolt
Solymosi Tams
Basa-Dnes Orsolya
Jordn Tams
Angi Rka
Original Assignee
Druggability Tech Ip Holdco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Druggability Tech Ip Holdco Ltd filed Critical Druggability Tech Ip Holdco Ltd
Publication of AR103653A1 publication Critical patent/AR103653A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fórmulas complejas farmacéuticamente aceptables que comprenden complejos de acetato de abiraterona y excipientes farmacéuticamente aceptables, proceso para prepararlas y composiciones farmacéuticas que las contienen. La fórmula compleja de la presente presenta propiedades fisicoquímicas superiores que tienen como consecuencia un menor efecto con los alimentos, por lo cual puede empleársela en una dosis significativamente menor y no es necesario tomarla con el estómago vacío. Reivindicación 1: Un complejo estable caracterizado porque presenta características fisicoquímicas y un rendimiento biológico superiores, que comprende (a) acetato de abiraterona como compuesto activo, o una combinación de compuestos activos que incluye acetato de abiraterona; (b) al menos un agente formador de complejos que se selecciona entre los glicéridos de polietilenglicol que están compuestos por monoglicéridos, diglicéridos o triglicéridos y monoésteres o diésteres de polietilenglicol, la hidroxipropilcelulosa, los poloxámeros, la vinilpirrolidona / el acetato de vinilo, el polietilenglicol, la poli(2-etil-2-oxazolina), la polivinilpirrolidona, los copolímeros de bloques a base de óxido de etileno y óxido de propileno, el poli(ácido maleico / éter de metil vinilo), los copolímeros injertados a base de polivinilcaprolactama-acetato de polivinilo-polietilenglicol, el hidroxiestearato de polioxilo 15, los copolímeros de bloques a base de óxido de etileno / propileno, los copolimeros injertados a base de alcohol polivinílico y polietilenglicol y el succinato de d-a tocoferil polietilenglicol 1000; y (c) de resultar deseable, diversos excipientes farmacéuticamente aceptables; donde el complejo comprende partículas cuyo tamaño es inferior a 600 nm y presenta una o más de las siguientes características: puede ser redispersado de manera instantánea en medios relevantes desde el punto de vista fisiológico; presenta una velocidad de disolución superior; es estable en una forma sólida o en una en solución o una dispersión coloidal; presenta una solubilidad aparente en el agua de al menos 0,6 mg/ml; en un análisis con rayos X, presenta una forma sólida con un carácter amorfo; presente una permeabilidad PAMPA de el menos 0,5 × 10⁻⁶ cm/s cuando se lo dispersa en agua destilada, la cual no se reduce con el tiempo durante un período de al menos 3 meses; no presenta un efecto positivo con los alimentos (se caracteriza por una proporción entre el estado alimentado y el ayuno que es inferior a 1,25), por lo cual es posible administrarlo en una dosis significativamente menor y no es necesario tomarlo con el estómago vacío; la variabilidad de su exposición es significativamente menor que la que puede obtenerse con Zytiga.
ARP160100363A 2015-02-09 2016-02-10 Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen AR103653A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1500055A HUP1500055A1 (hu) 2015-02-09 2015-02-09 Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények

Publications (1)

Publication Number Publication Date
AR103653A1 true AR103653A1 (es) 2017-05-24

Family

ID=89991732

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100363A AR103653A1 (es) 2015-02-09 2016-02-10 Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen

Country Status (18)

Country Link
US (4) US9623034B2 (es)
EP (1) EP3256108B1 (es)
JP (1) JP6697473B2 (es)
CN (1) CN107278152A (es)
AR (1) AR103653A1 (es)
AU (1) AU2016217534A1 (es)
BR (1) BR112017017089A2 (es)
CA (1) CA2976053A1 (es)
ES (1) ES2737955T3 (es)
HK (1) HK1246189B (es)
HU (2) HUP1500055A1 (es)
IL (1) IL253793B (es)
MX (1) MX2017010280A (es)
PL (1) PL3256108T3 (es)
RU (1) RU2017129740A (es)
SG (1) SG11201706273QA (es)
TW (1) TWI696463B (es)
WO (1) WO2016128891A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500055A1 (hu) 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
CN110022901A (zh) 2016-12-14 2019-07-16 成药技术Ip控股有限公司 含有塞来昔布的药物组合物
JP2020502144A (ja) * 2016-12-19 2020-01-23 ドラッガビリティー テクノロジーズ アイピー ホールディング カンパニー リミテッドＤｒｕｇｇａｂｉｌｉｔｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｐ Ｈｏｌｄｃｏ Ｌｉｍｉｔｅｄ スボレキサントの医薬製剤
AU2018316248A1 (en) * 2017-08-09 2020-01-30 Nangenex Nanotechnology Incorporated Pharmaceutical composition comprising Abiraterone acetate and Darulotamide
CN111617258A (zh) * 2019-02-28 2020-09-04 江苏恒瑞医药股份有限公司 一种制备阿比特龙或其衍生物药物组合物的方法及其应用
CZ2019168A3 (cs) 2019-03-20 2020-09-30 Zentiva, K.S. Farmaceutická kompozice obsahující abirateron acetát
CN110170058B (zh) * 2019-06-24 2022-02-11 李建恒 一种阿比特龙包合物及其制备方法
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
CN117881411A (zh) * 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO1995011914A1 (en) 1993-10-27 1995-05-04 Merrell Pharmaceuticals Inc. Δ16 unsaturated c¿17? heterocyclic steroids useful as steroid c17-20 lyase inhibitors
US5688977A (en) 1996-02-29 1997-11-18 Napro Biotherapeutics, Inc. Method for docetaxel synthesis
EP1608339B8 (en) 2003-02-28 2012-04-25 McNeill-PPC, Inc. Pharmaceutical co-crystal of celecoxib-nicotinamide
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2009009132A1 (en) 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
US9278134B2 (en) 2008-12-29 2016-03-08 The Board Of Trustees Of The University Of Alabama Dual functioning ionic liquids and salts thereof
CN101768199B (zh) 2009-12-24 2014-03-26 深圳万乐药业有限公司 醋酸阿比特龙的多晶型物及其制备方法
HUP1000325A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
CN102558275A (zh) 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
CA2832410C (en) * 2011-04-15 2019-07-23 Janssen Pharmaceutica Nv Freeze dried drug nanosuspensions
CN102321142A (zh) 2011-09-29 2012-01-18 重庆医药工业研究院有限责任公司 一种醋酸阿比特龙晶型及其制备方法
CN102336801B (zh) 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
US9662807B2 (en) * 2011-12-21 2017-05-30 GKN Aerospace Services Structures, Corp. Method for forming a fabric preform for a composite material by separately tensioning tows
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014083512A1 (en) 2012-11-28 2014-06-05 Dr. Reddy's Laboratories Limited Process for preparation of abiraterone acetate
WO2014100418A2 (en) 2012-12-20 2014-06-26 Kashiv Pharma, Llc Orally disintegrating tablet formulation for enhanced bioavailability
EP2938625B1 (en) 2012-12-31 2018-02-21 Hetero Research Foundation Process for the preparation of abiraterone acetate
KR102121404B1 (ko) * 2013-03-15 2020-06-11 썬 파마 글로벌 에프제트이 아비라테론 아세테이트 제제
EP2813212A1 (en) * 2013-06-10 2014-12-17 Zentiva, a.s. Drug formulation using API in nanofibers
HUP1500055A1 (hu) 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények

Also Published As

Publication number Publication date
US9592244B2 (en) 2017-03-14
US10130582B2 (en) 2018-11-20
RU2017129740A (ru) 2019-03-11
HK1246189B (zh) 2020-03-27
EP3256108A1 (en) 2017-12-20
WO2016128891A1 (en) 2016-08-18
HUP1500055A1 (hu) 2016-08-29
TW201639580A (zh) 2016-11-16
PL3256108T3 (pl) 2019-12-31
TWI696463B (zh) 2020-06-21
US20170182172A1 (en) 2017-06-29
JP2018504443A (ja) 2018-02-15
US20160228455A1 (en) 2016-08-11
US10668016B2 (en) 2020-06-02
MX2017010280A (es) 2017-12-04
ES2737955T3 (es) 2020-01-17
SG11201706273QA (en) 2017-08-30
CN107278152A (zh) 2017-10-20
IL253793A0 (en) 2017-09-28
US20160331763A1 (en) 2016-11-17
JP6697473B2 (ja) 2020-05-20
RU2017129740A3 (es) 2019-08-06
HUE045398T2 (hu) 2019-12-30
US9623034B2 (en) 2017-04-18
US20190046437A1 (en) 2019-02-14
AU2016217534A1 (en) 2017-09-07
IL253793B (en) 2021-02-28
EP3256108B1 (en) 2019-05-01
BR112017017089A2 (pt) 2018-06-26
CA2976053A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
AR103653A1 (es) Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen
JP2018504443A5 (es)
US20100143481A1 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
JP2015531377A5 (es)
TWI654981B (zh) 包含度他雄胺和丙二醇單月桂酸酯的醫藥組成物及其製備方法
JP2010150289A (ja) 分子分散されたドロスピレノンを含む組成物
JP2007528901A5 (es)
JP2006514119A (ja) 溶解率が向上した難溶性薬剤の溶媒系
WO2004017958A1 (ja) 軟カプセル剤
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
KR101590072B1 (ko) 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
AR098389A1 (es) Complejos de fulvestrant y sus derivados, proceso para su preparación y composiciones farmacéuticas que los contienen
AU2015308614B2 (en) Pharmaceutical composition and methods
JP2015516418A5 (es)
US20240074968A1 (en) Oral pharmaceutical composition and method for producing particulate formulation comprising composition
RU2016150868A (ru) Пероральная фармацевтическая композиция изотретиноина
JPWO2009031318A1 (ja) 鎮痛・抗炎症剤含有外用剤
JP2017530149A (ja) 低用量経口イソトレチノイン医薬組成物
JP2017508815A (ja) 液状医薬組成物
KR20200023473A (ko) 두타스테라이드를 포함하는 고형 제제 및 이의 제조방법
JP5750278B2 (ja) カンデサルタンシレキセチルのカプセル充填用組成物
RU2021102950A (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
JP2010059058A (ja) 鎮痛・抗炎症剤含有外用剤
CN111565712A (zh) 一种固体微粒及其制备方法和含其的药物组合物
JP2010006771A (ja) 鎮痛・抗炎症剤含有外用剤

Legal Events

Date Code Title Description
FB Suspension of granting procedure